文献速递炎症性肠病

生物制剂预防克罗恩病患者穿透性并发症的疗效比较

Comparative Effectiveness of Biologic Therapies in Preventing Penetrating Complications in Patients With Crohn's Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-09-04

该研究基于Merative商业数据库(2006–2020年),纳入40,693例首次使用生物制剂的成人克罗恩病患者,比较抗TNF、乌司奴单抗和维得利珠单抗对管腔穿透性疾病(LPD)和肛周穿透性疾病(PPD)的风险。抗TNF较维得利珠单抗降低LPD和PPD风险,较乌司奴单抗降低LPD风险;维得利珠单抗与乌司奴单抗间无显著差异。

要点

  • 抗TNF较维得利珠单抗降低LPD风险(HR 0.66,95%CI 0.55–0.78,P<.0001)。
  • 抗TNF较维得利珠单抗降低PPD风险(HR 0.88,95%CI 0.80–0.96,P=.0045)。
  • 维得利珠单抗与乌司奴单抗在LPD和PPD风险上无显著差异。

核心结论

  • 抗TNF治疗与较低的LPD和PPD风险相关(对比维得利珠单抗),并与较低的LPD风险相关(对比乌司奴单抗)。
  • 需进一步研究验证这些发现并确定差异的潜在原因。

研究设计与样本

  • 基于Merative商业数据库(2006–2020年)的队列研究,纳入年龄>17岁、首次使用生物制剂(抗TNF、乌司奴单抗或维得利珠单抗)的克罗恩病患者。
  • 排除既往存在穿透性疾病者,最短回溯期为1年;采用逆概率治疗加权平衡年龄、性别、合并症、既往克罗恩病手术和疾病严重程度。
  • 采用Cox比例风险模型进行成对比较,校正免疫调节剂暴露,生物制剂暴露作为时间依赖变量(药物持有率0.8)。

主要发现

  • 共纳入40,693例患者:93%使用抗TNF,3%使用乌司奴单抗,4%使用维得利珠单抗。
  • 逆概率治疗加权后所有比较均平衡良好。
  • 抗TNF对比维得利珠单抗:LPD风险HR 0.66(95%CI 0.55–0.78,P<.0001),PPD风险HR 0.88(95%CI 0.80–0.96,P=.0045)。
  • 抗TNF对比乌司奴单抗:LPD风险HR 0.37(95%CI 0.30–0.46,P<.0001)。
  • 维得利珠单抗与乌司奴单抗在LPD和PPD风险上无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究验证这些发现并确定差异的潜在原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Comparative effectiveness of biologics in preventing penetrating disease (PD) in Crohn's disease (CD) is not well established. We compared the risk of developing luminal and perianal PD (LPD and PPD) between biologics used as first-line therapies. METHODS: Adults (>17 years) with CD who initiated their first biologic (anti-tumor necrosis factor [anti-TNF], ustekinumab [UST], or vedolizumab [VDZ]) were identified from Merative Commercial Database (2006 and 2020). We excluded preexisting PD using a minimum look-back period of 1 year. Cohorts were balanced by inverse probability of treatment weighting based on age, sex, comorbidities, prior CD surgery, and CD severity. Pairwise comparisons were performed by Cox proportional hazards models, adjusted for immunomodulator exposure, and with biologic exposure treated as a time-dependent variable based on a medication possession ratio of 0.8. RESULTS: Our analysis included 40,693 patients: 93% anti-TNF, 3% UST, and 4% VDZ. After inverse probability of treatment weighting all comparisons were well balanced. Anti-TNF was protective against LPD (hazard ratio, 0.66; 95% confidence interval, 0.55-0.78; P < .0001) and PPD (hazard ratio, 0.88; 95% confidence interval, 0.80-0.96; P = .0045) compared with VDZ and LPD (hazard ratio, 0.37; 95% confidence interval, 0.30-0.46; P < .0001) compared with UST. There were no significant differences in the risk of LPD and PPD between VDZ and UST. These results were similar after limiting the study period to after 2016. CONCLUSIONS: Anti-TNF therapy was associated with a lower risk of LPD and PPD compared with VDZ, and lower risk of LPD compared with UST. Further studies are needed to validate these findings and to determine potential reasons for these differences.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. McCurdy JD, Stwalley D, Olsen MA, et al. Comparative Effectiveness of Biologic Therapies in Preventing Penetrating Complications in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2023. PMID: 37673348. doi:10.1016/j.cgh.2023.08.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。